

Multiple Xanthoma Tuberosum in a Case of Familial Homozygous Hypercholesterolemia

Pankaj Singhania, Pritam Biswas, Abhranil Dhar

Department of Endocrinology and Metabolism,
Institute of Post Graduate Medical Education and Research – Seth Sukhlal Karnani Memorial Hospital, West Bengal, India

Key words: xanthoma, familial, hypercholesterolemia, LDL

A 15-year-old, Indian, female child of a second-degree consanguineous marriage, presented with polymorphic yellowish-brown nodular cutaneous lesions over the dorsal aspect of both elbows, knees (Figure 1A) and buttocks (Figure 1B). These were suggestive of xanthoma tuberosum and were first noted at 4 years old. There were no spots over the eyelids, acanthosis, skin tags or tendon xanthomas. Arcus juvenilis was not noted. A bilateral carotid bruit was appreciated. Her father and mother also have hypercholesterolemia and were receiving atorvastatin.

Her lipid profile showed total cholesterol: 790 mg/dL, LDL-C: 736 mg/dL, HDL-C: 34 mg/dL, VLDL-C: 124 mg/dL and triglyceride: 102 mg/dL. There was also increased carotid intima media thickness on doppler and severe aortic stenosis and normal Ejection fraction of 62% on echocardiogram.

Genomic studies revealed homozygous mutation in both alleles of the LDL-R gene, associated with autosomal dominant Familial Hypercholesterolemia. The 737-position arginine (R) was also changed. This change, previously reported by Mozas et al., in a Spanish patient,¹ was not present in genomic databases reviewed as of writing.

The patient was subsequently diagnosed with Homozygous Familial Hypercholesterolemia using the Simon Broome Register criteria.² Diet modification, atorvastatin and ezetimibe were started, followed by subcutaneous evolocumab. After 6-8 weeks of therapy with atorvastatin, ezetimibe and evolocumab, her cholesterol levels were markedly reduced by 82 and 89%, respectively. However, the patient discontinued the use of evolocumab due to financial constraints.



Figure 1. Large tuberous xanthomas on both knees (A) and buttocks (B).

Homozygous familial hypercholesterolemia is a disorder of lipoprotein metabolism from mutations in the low-density lipoprotein receptor (LDLR) gene,³ which manifests as xanthomas.⁴

Guidelines for dyslipidaemia recommend high intensity statin treatment at 6-10 years of age, with healthy lifestyle measures and use of PCSK-9 inhibitors for children with homozygous familial hypercholesterolemia. Goals for children >10 years of age are LDL-C <3.5 mmol/l (135 mg/dL) or at least a 50% reduction from the baseline.^{5,6}

Ethical Consideration

Patient consent was obtained before submission of the manuscript.

Statement of Authorship

The authors certified fulfilment of ICMJE authorship criteria.

CRediT Author Statement

PS: Conceptualization, Methodology, Software, Validation, Investigation, Resources, Writing – review and editing, Visualization, Supervision, Funding acquisition. **PB:** Conceptualization, Formal analysis, Data curation, Writing – original draft preparation, Visualization, Project administration. **AD:** Conceptualization, Formal analysis, Resources, Writing – original draft preparation, Visualization, Funding acquisition.

Author Disclosure

The authors declared no conflict of interest.

Funding Source

None.

References

1. Mozas P, Cenarro A, Civeira F, Castillo S, Ros E, Pocovi M. Mutation analysis in 36 unrelated Spanish subjects with familial hypercholesterolemia: Identification of 3 novel mutations in the LDL receptor gene. *Hum Mutat.* 2000;15(5):483-4. PMID: 10790219. [https://doi.org/10.1002/\(SICI\)1098-1004\(200005\)15:5<483::AID-HUMU19>3.0.CO;2-Q](https://doi.org/10.1002/(SICI)1098-1004(200005)15:5<483::AID-HUMU19>3.0.CO;2-Q).
2. Risk of fatal coronary heart disease in familial hypercholesterolemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. *BMJ.* 1991; 303(6807):893-6. PMID: 1933004. PMCID: PMC1671226. <https://doi.org/10.1136/bmj.303.6807.893>.
3. Müller C. Angina pectoris in hereditary xanthomatotic. *Arch Intern Med (Chic).* 1939;64(4):675-700. <https://doi.org/10.1001/archinte.1939.00190040016002>.
4. Kasper DL, Fauci AS, Hauser S, et al. *Harrison's principles of internal medicine*, 19th ed., vol. 2. New York: McGraw-Hill; 2015.
5. Maliachova O, Stabouli S. Familial hypercholesterolemia in children and adolescents: Diagnosis and treatment. *Curr Pharm Des.* 2018;24(31):3672-7. PMID: 30317987. <https://doi.org/10.2174/1381612824666181010145807>.
6. Mach F, Baigent C, Catapano A; for The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. *European Heart Journal.* 2020;41(1); 111-188. <https://doi.org/10.1093/eurheartj/ehz455>.

Authors are required to accomplish, sign and submit scanned copies of the JAFES Author Form consisting of: (1) Authorship Certification, that authors contributed substantially to the work, that the manuscript has been read and approved by all authors, and that the requirements for authorship have been met by each author; (2) the Author Declaration, that the article represents original material that is not being considered for publication or has not been published or accepted for publication elsewhere, that the article does not infringe or violate any copyrights or intellectual property rights, and that no references have been made to predatory/suspected predatory journals; (3) the Author Contribution Disclosure, which lists the specific contributions of authors; (4) the Author Publishing Agreement which retains author copyright, grants publishing and distribution rights to JAFES, and allows JAFES to apply and enforce an Attribution-Non-Commercial Creative Commons user license; and (5) the Conversion to Visual Abstracts (*optional for original articles only) to improve dissemination to practitioners and lay readers. Authors are also required to accomplish, sign, and submit the signed ICMJE form for Disclosure of Potential Conflicts of Interest. For original articles, authors are required to submit a scanned copy of the Ethics Review Approval of their research as well as registration in trial registries as appropriate. For manuscripts reporting data from studies involving animals, authors are required to submit a scanned copy of the Institutional Animal Care and Use Committee approval. For Case Reports or Series, and Images in Endocrinology, consent forms, are required for the publication of information about patients; otherwise, appropriate ethical clearance has been obtained from the institutional review board. Articles and any other material published in the JAFES represent the work of the author(s) and should not be construed to reflect the opinions of the Editors or the Publisher.



Clinical controversies and disease updates are also welcome. Instructions to Authors available at www.ASEAN-endocrinejournal.org.